Highlights Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
3.36 ^USD	-5.88%		-3.72%	-12.50%

05-08	Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study	MT
05-08	Acumen Pharmaceuticals, Inc. Announces First Patient Dosed in Altitude-Ad, A Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer?S Disease	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study	05-08	MT
Acumen Pharmaceuticals, Inc. Announces First Patient Dosed in Altitude-Ad, A Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer?S Disease	05-08	CI
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	04-04	MT
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04-04	MT
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04-04	CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Acumen Pharmaceuticals, Inc. Presents Sabirnetug Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting	03-08	CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Halozyme Therapeutics Signs Non-Exclusive License Deal With Acumen Pharmaceuticals for Enhanze Technology	11-06	MT
Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease	23-10-27	CI
Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer?s During Symposium At the 16Th Annual Clinical Trials on Alzheimer?s Disease	23-10-04	CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Acumen Pharmaceuticals, Inc. Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimerâ€™s Disease at the Alzheimerâ€™s Association International Conference 2023	23-07-16	CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Acumen Pharmaceuticals, Inc. Presents in Vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer's Disease	23-03-28	CI
ACUMEN PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-27	AQ
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Acumen Pharmaceuticals : Corporate Presentation	23-03-26	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Highlights

Filters